Management is prioritizing a return to top-line growth through renewed customer framework agreements and selective pricing investments to support volume, with customer engagement up and the innovation pipeline growing double digits. Tate & Lyle expects cost synergies to exceed $50m by end-FY27 and continues a five-year $200m productivity programme to help mitigate pricing investments.
Cyborg Score Rationale
Revenue and EBITDA are expected to decline by low single digits in constant currency for the year ending March 2026, presenting near-term headwinds. However, cross-selling pipeline is up 33% and the innovation pipeline is growing double digits, signaling underlying momentum. The CP Kelco acquisition adds scale but integration complexity.
Top Insights
Q3 reported group revenue rose ~15% after including CP Kelco acquisition completed in November 2024
Fiber fortification is a major global demand theme, with growing engagement particularly in beverages and dairy in the U.S., Europe, and Asia
CP Kelco integration targeting up to $70m revenue synergies by FY29 alongside $50m+ cost synergies by FY27
Company employs nearly 5,000 people and operates in over 120 countries with most revenue generated in North America
Named Competitors
Ingredion — Specialty ingredients provider; starches and sweetening solutions
Glanbia — Nutritional and ingredient solutions provider
CP Kelco — Specialty hydrocolloids and functional gums (acquired Nov 2024)
Recent Developments
(March 2026) Q3 trading in line with expectations; management prioritizing return to top-line growth with renewed customer framework agreements and 33% cross-selling pipeline growth
(November 2024) Completed merger/acquisition of CP Kelco
(FY2026) Revenue and EBITDA guidance maintained at expected low single-digit decline in constant currency
Open the full interactive Tate & Lyle plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.